

May 4, 2015

As of May 1, Novozymes has purchased an accumulated 1,983,921 shares with a transaction value of DKK 633.9 million under the stock buyback program Novozymes announced in Company announcement No. 6, 2015 and initiated February 2, 2015. Under the program, Novozymes will buy back B shares worth up to DKK 2 billion in total during 2015.

The following transactions have been made under the program in accordance with the provisions of European Commission Regulation (EC) No. 2273/2003 of 22 December 2003, also referred to as the Safe Harbour Regulation:

	Number of shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	1,836,203		587,629,043
27 April 2015	29,940	322.75	9,663,170
28 April 2015	45,000	315.01	14,175,451
29 April 2015	45,000	310.12	13,955,468
30 April 2015	27,778	306.33	8,509,142
1 May 2015	-	-	-
Accumulated under the program	1,983,921		633,932,274

In addition, transactions necessitated by Novozymes' previously established incentive programs have resulted in a net sale by Novozymes of 12,465 B shares in the period from April 27 to May 1, 2015. The share transactions related to the incentive programs were not part of the Safe Harbour stock buyback program.

Following the transactions stated above, Novozymes owns a total of 5,912,408 treasury shares, corresponding to 1.9% of the stock capital. The total number of shares in the company is 313,000,000, including treasury shares.

## Contact information

Investor Relations:

Thomas Bomhoff (DK)	+45 3077 1226	tsbm@novozymes.com
Klaus Sindahl (DK)	+45 5363 0134	ksdh@novozymes.com
Martin Riise (USA)	+1 919 649 2565	mrsn@novozymes.com

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at <a href="https://www.novozymes.com">www.novozymes.com</a>.

CVR number: 10 00 71 27